Get the Stockscreener App
5.00
1.21%
0.06
Trisalus Life Sciences Inc stock is traded at $5.00, with a volume of 165.59K.
It is up +1.21% in the last 24 hours and up +1.83% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$4.94
Open:
$4.99
24h Volume:
165.59K
Relative Volume:
0.93
Market Cap:
$299.06M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-2.8536
EPS:
-1.7522
Net Cash Flow:
-
1W Performance:
-7.75%
1M Performance:
+1.83%
6M Performance:
-2.91%
1Y Performance:
-12.28%
1-Day Range:
$4.86
$5.125
1-Week Range:
$4.81
$5.58
52-Week Range:
$3.42
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.00 | 295.47M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TLSI SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Exploring TriSalus Life Sciences's Earnings Expectations - Benzinga
Northland Securities Forecasts TLSI FY2025 Earnings - MarketBeat
TLSIW Stock Price, News & Analysis - Stock Titan
TriSalus Life Sciences Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
TLSI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
TriSalus to Raise $40M from Stock Sale - National Today
TLSIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Retail Surge: What are TriSalus Life Sciences Inc Equity Warrants growth levers2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
TriSalus Life Sciences (TLSI) to Release Earnings on Thursday - Defense World
TLSI PE Ratio & Valuation, Is TLSI Overvalued - Intellectia AI
TriSalus Life Sciences (NASDAQ: TLSI) raises ~$40M in 9.76M-share offering - Stock Titan
Cancer-focused medtech company TriSalus sets March 5 call on 2025 results - Stock Titan
TriSalus prices $40 mln public stock offering - MSN
TLSI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Insider Buying: David Patience Acquires Shares of TriSalus Life Sciences Inc (TLSI) - GuruFocus
TLSI | TriSalus Life Sciences, Inc. Insider Trading - Quiver Quantitative
TLSI | TriSalus Life Sciences, Inc. FinancialsIncome Statement - Quiver Quantitative
TriSalus Life Sciences (TLSI) CFO adds 3,657 shares in open-market buy - Stock Titan
TriSalus director Gary Gordon buys 9,756 shares (TLSI) in open market - Stock Titan
Director William Valle adds 30,487 TriSalus (TLSI) shares - Stock Titan
TriSalus Life Sciences (TLSI) CEO purchases 30,487 common shares - Stock Titan
TriSalus Life Sciences (TLSI) director adds 361,098 shares in open-market buys - Stock Titan
TriSalus Life Sciences announces plans for public offering - Medical Buyer
TriSalus prices $40M public offering at $4.10 per share By Investing.com - Investing.com South Africa
TriSalus Life Sciences Prices Underwritten Public Equity Offering - TipRanks
TriSalus (TLSI) to raise about $40M in underwritten stock sale - Stock Titan
TriSalus to raise $40M from stock sale - BizWest
TriSalus Life Sciences Prices Stock Offering at $4.10 a Share - marketscreener.com
TriSalus prices $40M public offering at $4.10 per share - Investing.com
Cancer-focused medical tech firm TriSalus raises $40M at $4.10 a share - Stock Titan
Cancer-focused TriSalus Life Sciences plans new stock sale - Stock Titan
Volume Summary: How does TriSalus Life Sciences Inc score in quality rankings2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Risk Hedge: What is TriSalus Life Sciences Inc Equity Warrants P E ratio telling usJuly 2025 Action & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Will TriSalus Life Sciences Inc. benefit from rate cutsEarnings Miss & AI Enhanced Market Trend Forecasts - mfd.ru
Is TriSalus Life Sciences Inc. Equity Warrant forming a bullish divergenceJuly 2025 PostEarnings & Free High Accuracy Swing Entry Alerts - mfd.ru
Published on: 2026-02-14 13:02:33 - mfd.ru
Is TriSalus Life Sciences Inc. Equity Warrant stock a value trapJuly 2025 Update & Entry Point Confirmation Signals - mfd.ru
TriSalus Life Sciences swaps board members - BizWest
Aug Rallies: Is TriSalus Life Sciences Inc Equity Warrants growth already priced inCEO Change & Safe Entry Trade Signal Reports - baoquankhu1.vn
Downgrade Watch: What are the risks of holding TriSalus Life Sciences Inc Equity WarrantJuly 2025 Movers & Long Hold Capital Preservation Tips - baoquankhu1.vn
How supply chain issues affect TriSalus Life Sciences Inc. Equity Warrant stock2025 Earnings Surprises & Technical Analysis for Trade Confirmation - mfd.ru
Stansky reports major TriSalus (TLSI) stock and warrant holdings on Form 3 - Stock Titan
Investment Review: Is TriSalus Life Sciences Inc Equity Warrant a top pick in the sectorGDP Growth & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Dow Update: Why is TriSalus Life Sciences Inc stock going upGold Moves & Free Accurate Trade Setup Notifications - baoquankhu1.vn
TriSalus Life Sciences appoints Michael Stansky to board of directors By Investing.com - Investing.com South Africa
Trisalus Life Sciences appoints veteran healthcare investor Michael Stansky to its board of directors - marketscreener.com
TriSalus Life Sciences appoints Michael Stansky to board of directors - Investing.com
TriSalus Life Sciences Announces New Board Appointment - TipRanks
40-year healthcare dealmaker joins cancer-tech firm TriSalus board - Stock Titan
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors - marketscreener.com
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):